A New Paradigm for Gene Therapy R&D

The U.S. Food and Drug Administration (FDA), through its Center for Biologics Evaluation and Research (CBER), has released a draft guidance in June 2026 to support the efficient development of Cell and Gene Therapies (CGT). The core of this guidance is to allow developers to leverage Platform Knowledge gained from previous pipeline development or publicly available scientific data in the development of new drugs. This is a significant step, as it recognizes accumulated data from previous development processes, enabling the omission of unnecessary repetitive testing in the development of genome editing therapies. This is unprecedented, as regulatory agencies are now explicitly formalizing the sharing and reuse of prior knowledge, which is expected to dramatically accelerate the industry's R&D speed.

Relaxed CMC Regulations and Flexible Process Validation

Prior to this, in May 2026, the FDA finalized and immediately implemented flexible guidelines for Chemistry, Manufacturing, and Controls (CMC) requirements for cell and gene therapies. Traditional regulatory frameworks for biologics have struggled to fully reflect the unique characteristics of gene therapy manufacturing processes, which often target small patient populations or are customized for individual patients. With this guidance, the FDA will allow for progressive process verification by not specifying the minimum number of Process Performance Qualification (PPQ) batches. This is considered a concrete practical support measure that significantly reduces the high CMC entry barriers for venture biotech companies with small-scale production structures.

Integration of Safety Verification and Next-Generation Analytical Technologies

The guidelines have also been updated to incorporate the latest Next-Generation Sequencing (NGS) technology for safety assessment, another regulatory hurdle for genome editing therapies. The policy is to actively accept NGS-based sequencing data to precisely monitor off-target effects, which are unintended genetic modifications. This is also a process of incorporating the genomic analysis standards that leading companies such as CRISPR Therapeutics (CRSP) have already validated in clinical trials into the official regulatory pathway. Now, if latecomers build reliable genomic analysis platforms, they will be able to significantly reduce the time and cost required to demonstrate toxicological data.

Rapidly Growing Gene Therapy Market and Global Competitive Landscape

The global cell and gene therapy (CGT) market is rapidly expanding, with a size of at least $10.44 billion to $44.75 billion in 2026, with North America accounting for approximately 50% of the market share. Currently, the first CRISPR gene editing therapy, 'Casgevy (exagamglogene autotemcel),' is available on the market and is expanding its commercial reach for patients with sickle cell disease. Companies such as Beam Therapeutics (BEAM) and Intellia Therapeutics (NTLA), which are based on genome editing, are preparing to accelerate the early clinical entry of their follow-up pipelines based on this regulatory easing. In particular, as the Asia-Pacific (APAC) region is emerging as a new powerhouse, the U.S.'s regulatory innovation can also be seen as a strategic move to further solidify its country's bio-ecosystem leadership.